Tarsus Pharmaceuticals, Inc.
HealthcareNASDAQ:TARS · NASDAQ Global Select
-$0.66 today
Vol 0.26M · Avg 0.61M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-19.3%
avg -2.7%
ROIC
-16.6%
avg -30.1%
ROA
-11.8%
avg -25.9%
Analysis
ROA is currently the strongest return metric at -11.8% versus its period average of -25.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bobak R. Azamian | Co-Founder, President, Chief Executive Officer & Chairman | $1.32M | — | — | $33,421.00 | 0.08% |
Jeffrey S. Farrow | Chief Financial Officer & Chief Strategy Officer | $888,645.00 | — | 64 | $43,316.00 | 0.10% |
Seshadri Neervannan | Chief Operating Officer | $839,200.00 | — | 58 | $82,791.00 | 0.19% |
Aziz Mottiwala | Chief Commercial Officer | $821,650.00 | — | 48 | $61,480.00 | 0.14% |
Bryan Wahl | General Counsel & Corporate Secretary | $771,233.00 | — | 48 | $63,959.00 | 0.15% |
Dianne C. Whitfield | Chief Human Resources Officer | $578,900.00 | — | 49 | $35,028.00 | 0.08% |
Elizabeth Yeu | Chief Medical Officer | $156,691.00 | — | 47 | $23,308.00 | 0.05% |
Scott Youmans | Vice President of Sales | — | — | — | $4,684.00 | 0.01% |
Adrienne Kemp | Senior Director of Corporate Communications | — | — | — | — | — |
Cara Miller | Senior Vice President of Corporate Affairs | — | — | — | — | — |
Neera Clase | Senior Vice President of Market Access | — | — | — | — | — |
David Nakasone | Head of Investor Relations | — | — | — | $0.00 | <0.01% |
Matthew Rossen | Vice President of Marketing | — | — | 48 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
44
$15.08M
Net Sentiment
$15.08M
Net selling
Most Active
LINK WILLIAM J PHD
9 transactions
1–10 of 44
Analysis
Insiders reported 0 buys worth $0.00 and 44 sells worth $15.08M over the last 12 months. That adds up to net selling of $15.08M. LINK WILLIAM J PHD was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +65.5% (8yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +65.5% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.25B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$4.84B
Celcuity Inc.
NASDAQ:CELC
$4.32B
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
$3.05B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Ascentage Pharma Group International
NASDAQ:AAPG
$409.04M
Who manages TARS?
Tarsus Pharmaceuticals, Inc. (TARS) lists 13 active executives. The top listed executive is Bobak R. Azamian, Co-Founder, President, Chief Executive Officer & Chairman.
Are TARS insiders buying or selling?
Recent insider activity shows net buying of $16.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.